Sunesis Announces Data From Phase 2 Clinical Program Of Voreloxin In Acute My bi13511123 Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced updated data from Phase 2 studies of the Company's lead drug candidate, voreloxin, acute myeloid leukemia (AML) and platinum-resistant ovarian cancer. The results were presented today at the 2010 American Society of Oncology (ASCO) Annual Meeting Chicago, Illinois. The presentations are available on the ..

NKTR-102 Has High Response Rate and Sustained Clinical Benefit 48 Percent bi13511123 CHICAGO, June 6 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from a Phase 2 study evaluating single-agent NKTR-102 women platinum-resistant/refractory ovarian cancer

MethylGene Presents Encouraging Clinical and Preclinical Data for MGCD265 at bi13511123 MethylGene Inc. (TSX: MYG) today disclosed preliminary and pre data for MGCD265 poster presentations at the American Society of Oncology (ASCO) 2010 Annual Meeting held Chicago, IL. In addition, the Company providing a preliminary update on Trial 103 (the first stage of the Phase II program) MGCD265 administered combination either erlotinib ..

Antibody therapy lengthens survival of metastatic melanoma patients large bi13511123 A therapy that multiplies the effect of a natural disease-fighting antibody has extended the lives of patients metastatic melanoma a large, international trial. The study's researchers report findings simultaneously at the American Society of Oncology annual meeting Chicago and the New England Journal of Medicine

Sunesis Announces Data From Phase 2 Clinical Program of Voreloxin Acute My bi13511123 Updated, Positive Phase 2 Data AML and Ovarian Cancer Presented at the ASCO 2010 Annual Meeting; Sunesis to Host Conference Call Tuesday, June 8th at 9:00 AM Eastern Time..

No Benefit In Prevention Of Lung Cancer In Clinical Trial Of Selenium bi13511123 Selenium, a supplement taken daily by millions hopes of protection against cancer and a host of other diseases, has proven to be of no benefit reducing a patient's risk of developing lung cancer - either a recurrence or second primary malignancy, according to results of an international Phase III trial. Results from the decade-long study, initiated by the Eastern Cooperative ..

Sunesis Announces Data From Phase 2 Clinical Program Of Voreloxin In Acute My bi13511123 Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced updated data from Phase 2 studies of the Company's lead drug candidate, voreloxin, acute myeloid leukemia (AML) and platinum-resistant ovarian cancer. The results were presented today at the 2010 American Society of Oncology (ASCO) Annual Meeting Chicago, Illinois. The presentations are available on the ..

NKTR-102 Has High Response Rate and Sustained Clinical Benefit 48 Percent bi13511123 CHICAGO, June 6 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from a Phase 2 study evaluating single-agent NKTR-102 women platinum-resistant/refractory ovarian cancer

MethylGene Presents Encouraging Clinical and Preclinical Data for MGCD265 at bi13511123 MethylGene Inc. (TSX: MYG) today disclosed preliminary and pre data for MGCD265 poster presentations at the American Society of Oncology (ASCO) 2010 Annual Meeting held Chicago, IL. In addition, the Company providing a preliminary update on Trial 103 (the first stage of the Phase II program) MGCD265 administered combination either erlotinib ..

Antibody therapy lengthens survival of metastatic melanoma patients large bi13511123 A therapy that multiplies the effect of a natural disease-fighting antibody has extended the lives of patients metastatic melanoma a large, international trial. The study's researchers report findings simultaneously at the American Society of Oncology annual meeting Chicago and the New England Journal of Medicine

Sunesis Announces Data From Phase 2 Clinical Program of Voreloxin Acute My bi13511123 Updated, Positive Phase 2 Data AML and Ovarian Cancer Presented at the ASCO 2010 Annual Meeting; Sunesis to Host Conference Call Tuesday, June 8th at 9:00 AM Eastern Time..

No Benefit In Prevention Of Lung Cancer In Clinical Trial Of Selenium bi13511123 Selenium, a supplement taken daily by millions hopes of protection against cancer and a host of other diseases, has proven to be of no benefit reducing a patient's risk of developing lung cancer - either a recurrence or second primary malignancy, according to results of an international Phase III trial. Results from the decade-long study, initiated by the Eastern Cooperative ..

FDA review finds flaws clinical trial for diabetes drug Avandia - Boston G bi13511123 Daily MailFDA review finds flaws trial for diabetes drug AvandiaBoston GlobeBy Christopher Rowland, Globe Staff WASHINGTON ? A key trial that drug maker GlaxoSmithKline has relied upon to defend the risk profile of Avandia, US experts urge limits for some drug safety trialsReutersFDA to consider fate of diabetes drug AvandiaUSA TodayFDA pokes holes study defending AvandiaCNN (blog)FiercePharma -Kansas City Star -Nature.com (blog)all 713 news articles »..

Genuine Honda Accessories - Home